Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a beardown 2nd quarter, and Wall Street noticed.

The drugmaker beat income expectations crossed its biggest franchises, raised its full-year outlook, and gave analysts caller reasons to enactment bullish heading into the backmost fractional of 2026.

Bank of America was 1 of them. The slope reiterated its Buy rating and kept its $162 terms target aft the report, good supra wherever the banal trades today.

One prevention fig successful peculiar caught BofA's attention, and it speaks straight to whether Gilead's adjacent maturation motor tin last.

Why Bank of America is lasting by Gilead banal aft net

Gilead reported second-quarter merchandise income of $7.6 billion, up of Wall Street estimates, driven by spot crossed its HIV, liver, and oncology franchises.

Bank of America Global Research kept its Buy standing and $162 terms people aft the print, according to a probe study shared with TheStreet. 

With the banal near $135, that people implies meaningful country to climb.

More Healthcare Stocks:

• UBS lifts Eli Lilly banal people to $1,425

• Morgan Stanley uncovers large Bristol Myers banal signals

• Goldman Sachs says 1 fig volition determination Eli Lilly stock

The institution raised full-year merchandise income guidance to $29.8 cardinal to $30.1 billion, up from a anterior scope of $29.4 cardinal to $29.8 billion.

Gilead present expects its HIV franchise to grow 9% to 10% this year, up from an earlier forecast of 8%.

The 70% fig driving Gilead's HIV prevention communicative

The fig BofA zeroed successful connected comes from Yeztugo, Gilead's twice-yearly HIV prevention shot.

Roughly a twelvemonth aft launch, more than 70% of patients were inactive connected the drug, a measurement the manufacture calls persistence.

Persistence simply tracks however galore patients enactment connected a medicine implicit time. High persistence means less radical quit, which supports steadier semipermanent revenue.

Gilead's absorption said the complaint is the highest crossed disposable PrEP options, the people of drugs taken to forestall HIV infection.

That matters due to the fact that persistence had been a unrecorded statement among investors. BofA said the beardown fig supports what it sees arsenic a ample commercialized accidental for the drug.

On the net call, Gilead added that much than 70% of Yeztugo users returned for their six-month reinjection, extending extortion for a afloat year, Investing.com reported. 

Gilead's HIV prevention and oncology launches are driving its 2026 growth.SOPA Images / Getty Images

Yeztugo and Descovy propulsion Gilead's PrEP income past $1 cardinal

Yeztugo posted second-quarter income of $232 million, up 40% from the anterior quarter.

Gilead inactive expects about $1 billion successful Yeztugo income for the afloat year, and the cause has go the starring prime for patients switching PrEP regimens.